

## **Enalapril Formulation**

Version 3.4	Revision Date: 09.04.2021	SDS Numbe 734752-000	
SECTIO	N 1: Identification o	f the substan	ce/mixture and of the company/undertaking
	u <b>ct identifier</b> e name	: Enalapril	Formulation
1.2 Relev	ant identified uses of	the substance	or mixture and uses advised against
	Use of the Sub- stance/Mixture		reutical
1.3 Detail	Is of the supplier of th	ne safety data s	sheet
Com	Company		& Co. on Street, 33nd floor ersey City, New Jersey, U.S.A
Telep	Telephone		6000
	E-mail address of person responsible for the SDS		WARD@organon.com
1 4 Emer	gency telephone num	her	

## 1.4 Emergency telephone number

215-631-6999

## **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

## Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1A Specific target organ toxicity - repeated exposure, Category 2

#### 2.2 Label elements

## Labelling (REGULATION (EC) No 1272/2008)

	.0)	A A A A A A A A A A A A A A A A A A A
Hazard pictograms		
Signal word	:	Danger
Hazard statements	:	H360D May damage the unborn child. H373 May cause damage to organs through prolonged or repeated exposure.
Precautionary statements :		Prevention:P201Obtain special instructions before use.P260Do not breathe dust.P280Wear protective gloves/ protective clothing/ eye protection/ face protection.

H360D: May damage the unborn child.

longed or repeated exposure.

H373: May cause damage to organs through pro-



## **Enalapril Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	734752-00011	Date of first issue: 07.06.2016
		<b>Response:</b> P308 + P313 attention.	IF exposed or concerned: Get medical advice/

#### Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

(S)-1-[N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleate

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

## **SECTION 3: Composition/information on ingredients**

## 3.2 Mixtures

## Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
(S)-1-[N-[1-(Ethoxycarbonyl)-3- phenylpropyl]-L-alanyl]-L-proline maleate	76095-16-4 278-375-7	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 1A; H360D STOT RE 1; H372 (Kidney, Cardio- vascular system)	>= 1 - < 10

For explanation of abbreviations see section 16.

## **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice	vi W	n the case of accident or if you feel unwell, seek medical ad- ice immediately. Vhen symptoms persist or in all cases of doubt seek medical dvice.
Protection of first-aiders	а	irst Aid responders should pay attention to self-protection, nd use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	-	inhaled, remove to fresh air. Set medical attention.
In case of skin contact		n case of contact, immediately flush skin with soap and plenty f water.



## **Enalapril Formulation**

Version 3.4	Revision Date: 09.04.2021	SDS Number: 734752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016		
		Get medical Wash clothir	ntaminated clothing and shoes. attention. ng before reuse. clean shoes before reuse.		
In cas	se of eye contact	•	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.		
lf swa	allowed	Get medical	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.		
4.2 Most i	important symptoms	and effects, both	acute and delayed		
Risks	3		e the unborn child. Jamage to organs through prolonged or repeated		
		the skin.	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.		
4.3 Indica	tion of any immedia		n and special treatment needed		

Treatment

: Treat symptomatically and supportively.

## **SECTION 5: Firefighting measures**

## 5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.

## 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.		
Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides		
5.3 Advice for firefighters				

Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment.



# **Enalapril Formulation**

Version 3.4	Revision Date: 09.04.2021	SDS Number: 734752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016		
			ray to cool unopened containers. amaged containers from fire area if it is safe to do a.		
SECTION	N 6: Accidental relea	se measures			
6.1 Perso	nal precautions, prote	ctive equipment a	nd emergency procedures		
Perso	onal precautions	Follow safe ha	protective equipment. andling advice (see section 7) and personal pro- nent recommendations (see section 8).		
6.2 Enviro	onmental precautions				
Environmental precautions		Prevent furthe Retain and dis Local authorit	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.		
6.3 Metho	ods and material for co	ntainment and cle	aning up		
Methods for cleaning up		tainer for disp Avoid dispers with compress Dust deposits es, as these r leased into the Local or natio posal of this n employed in t mine which re Sections 13 a	<ul> <li>Sweep up or vacuum up spillage and collect in suitable con tainer for disposal.</li> <li>Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).</li> <li>Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.</li> <li>Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.</li> <li>Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</li> </ul>		
6.4 Refere	ence to other sections				

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

## 7.1 Precautions for safe handling

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling.



## **Enalapril Formulation**

Versio 3.4	n Revision Date: 09.04.2021	SDS Number: 734752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016		
Hygiene measures		practice, bas sessment Keep contai Minimize du Keep contai Keep away Take precau Do not eat, o Take care to environmen : If exposure flushing sys place. Wher nated clothin The effective engineering appropriate industrial hy	<ul> <li>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment</li> <li>Keep container tightly closed.</li> <li>Minimize dust generation and accumulation.</li> <li>Keep container closed when not in use.</li> <li>Keep away from heat and sources of ignition.</li> <li>Take precautionary measures against static discharges.</li> <li>Do not eat, drink or smoke when using this product.</li> <li>Take care to prevent spills, waste and minimize release to the environment.</li> <li>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.</li> <li>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</li> </ul>		
7.2 Co	onditions for safe stor	age, including any in	compatibilities		
Requirements for storage areas and containers			perly labelled containers. Store locked up. Keep d. Store in accordance with the particular national		
A	dvice on common stora	age : Do not store Strong oxidi Organic per Explosives Gases			
<b>7.3 Specific end use(s)</b> Specific use(s)		: No data ava	ilable		

## **SECTION 8: Exposure controls/personal protection**

## 8.1 Control parameters

## Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Starch	9005-25-8	TWA OEL-RL (Respirable dust)	5 mg/m3	ZA OEL
	Further inform	ation: Recommende	ed Limit	
		TWA OEL-RL	10 mg/m3	ZA OEL
		(inhalable dust)	_	
	Further inform	ation: Recommende	ed Limit	
(S)-1-[N-[1- (Ethoxycarbonyl)- 3-phenylpropyl]-L- alanyl]-L-proline maleate	76095-16-4	TWA	50 μg/m3 (OEB 3)	Internal



## **Enalapril Formulation**

Version 3.4	Revision Date: 09.04.2021	SDS Number: 734752-00011	Date of last issue: 10.10.2 Date of first issue: 07.06.2		
		Wipe limit	500 µg/100 cm²	Internal	

#### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipm	ent	
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skip surfaces
		suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

## **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	powder white No data available No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han-



## **Enalapril Formulation**

Versi 3.4	on	Revision Date: 09.04.2021		S Number: 752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016
				dling or other me	eans.
		explosion limit / Upper bility limit	:	No data available	e
		explosion limit / Lower bility limit	:	No data available	e
١	Vapour	pressure	:	Not applicable	
F	Relative	e vapour density	:	Not applicable	
F	Relative	e density	:	No data available	e
[	Density		:	No data available	e
F	Partitior octanol	er solubility n coefficient: n-	:	No data available Not applicable No data available	
[	Decom	position temperature	:	No data available	e
٧	Viscosit Visc	ty osity, kinematic	:	Not applicable	
E	Explosi	ve properties	:	Not explosive	
(	Oxidizing properties		:	The substance o	r mixture is not classified as oxidizing.
9.2 O	)ther in	formation			
F	Flamma	ability (liquids)	:	No data available	e
F	Particle	size	:	No data available	e

## **SECTION 10: Stability and reactivity**

## 10.1 Reactivity

Not classified as a reactivity hazard.

## **10.2 Chemical stability**

Stable under normal conditions.

## 10.3 Possibility of hazardous reactions

Hazardous reactions	<ul> <li>May form explosive dust-air mixture during processing, han- dling or other means.</li> <li>Can react with strong oxidizing agents.</li> </ul>
10.4 Conditions to avoid	
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.



# **Enalapril Formulation**

ersion 4	Revision Date: 09.04.2021		9S Number: 4752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016
	npatible materials ials to avoid	:	Oxidizing age	nts
	rdous decompositio	-		I.
ECTION	111: Toxicological	infor	mation	
1.1 Inforr	mation on toxicologi	cal ef	fects	
Inform expos	nation on likely routes sure	of :	Inhalation Skin contact Ingestion Eye contact	
	<b>e toxicity</b> assified based on ava	ailable	information.	
<u>Produ</u>				
Acute	oral toxicity	:	Acute toxicity e Method: Calcu	estimate: > 2.000 mg/kg lation method
<u>Comp</u>	oonents:			
		yl)-3-j		alanyl]-L-proline maleate:
Acute	oral toxicity	:	LD50 (Rat): 2.0	000 - 3.500 mg/kg
			LDLo (Rat): 1.7	775 mg/kg
			LD50 (Mouse):	2.000 - 3.500 mg/kg
			LDLo (Mouse):	1.000 mg/kg
	toxicity (other routes istration)	of :		0 mg/kg ute: Intravenous
			LD50 (Mouse): Application Ro	750 mg/kg ute: Intravenous
			LD50 (Dog): >	100 mg/kg
			LDLo (Dog): 20	00 mg/kg
	corrosion/irritation assified based on ava	ailable	information.	
	oonents:			



# **Enalapril Formulation**

Version 3.4	Revision Date: 09.04.2021	SDS Number: 734752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016
	ous eye damage/eye lassified based on av		
	ponents:		
(S)-1-	-[N-[1-(Ethoxycarbo	nyl)-3-phenylpropyl]-	L-alanyl]-L-proline maleate:
Spec Resu		: Rabbit : Severe irritatio	n
Resp	iratory or skin sens	itisation	
•••••	sensitisation lassified based on av	ailable information.	
•	iratory sensitisatior		
-	lassified based on av ponents:	ailable information.	
		avi) 2 nhanvinranvil	Lalanyll Lanolino malaato:

## (S)-1-[N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleate:

:	Maximisation Test
:	Skin contact
:	Guinea pig
:	Not a skin sensitizer.
	:

## Germ cell mutagenicity

Not classified based on available information.

## **Components:**

(S)-1-[N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleated	e:
---	----

Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro sister chromatid exchange assay in mam- malian cells Result: negative
	Test Type: Alkaline elution assay Result: negative
Genotoxicity in vivo :	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative
	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Ingestion Result: negative



# **Enalapril Formulation**

ersion 4	Revision Date: 09.04.2021	SDS Number: 734752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016
	<b>logenicity</b> assified based on av	ailable information.	
Comp	onents:		
(S)-1-[	N-[1-(Ethoxycarbo	nyl)-3-phenylpropyl]-	L-alanyl]-L-proline maleate:
	ation Route ure time L	: Rat : Ingestion : 106 weeks : 90 mg/kg body : negative	veight
	ation Route ure time L	: Mouse : Ingestion : 94 weeks : 90 - 180 mg/kg : negative	g body weight
-	<b>ductive toxicity</b> amage the unborn c	nild.	
<u>Comp</u>	onents:		
(S)-1-[	N-[1-(Ethoxycarbo	nyl)-3-phenylpropyl]-	L-alanyl]-L-proline maleate:
Effects	s on fertility	Application Ro	male and female ute: Ingestion :L: 90 mg/kg body weight
Effects ment	s on foetal develop-		ute: Ingestion I Toxicity: NOAEL: 200 mg/kg body weight ects on foetal development
		Species: Rat Application Ro Developmenta Result: Fetoto:	I Toxicity: LOAEL: 1.200 mg/kg body weight
			I Toxicity: LOAEL: 30 mg/kg body weight on postnatal development, Effects on newborr
		Developmenta	
Repro	ductive toxicity - As-	: Positive evider	nce of adverse effects on development from



## **Enalapril Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	734752-00011	Date of first issue: 07.06.2016

STOT - single exposure

Not classified based on available information.

## STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

#### (S)-1-[N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleate:

Target Organs	:	Kidney, Cardio-vascular system
Assessment	:	Causes damage to organs through prolonged or repeated
		exposure.

#### **Repeated dose toxicity**

#### **Components:**

(S)-1-[N-[1-(Etho	xycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleate:
<b>o</b> ·	

Species:NOAEL:LOAEL:Application Route:Exposure time:Target Organs:	Dog 15 mg/kg 30 mg/kg Ingestion 1 yr Kidney
Species:NOAEL:Application Route:Exposure time:Remarks:	Rat 90 mg/kg Oral 1 yr No significant adverse effects were reported
Species:NOAEL:Application Route:Exposure time:Remarks:	Monkey 30 mg/kg Oral 1 Months No significant adverse effects were reported

## Aspiration toxicity

Not classified based on available information.

## Experience with human exposure

## **Components:**

(S)-1-[N-[1-(Ethoxycarbony	/ <b>I)-</b> 3-	phenylpropyl]-L-alanyl]-L-proline maleate:
Ingestion	:	Target Organs: Cardio-vascular system Symptoms: hypotension, Cough, Dizziness, Headache, Blurred vision, Fatigue, Oedema, Nausea, hyperkalemia, faint- ing, Weakness, skin rash Remarks: May cause harm to the unborn child.



## **Enalapril Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	734752-00011	Date of first issue: 07.06.2016

## **SECTION 12: Ecological information**

## 12.1 Toxicity

## Components:

## (S)-1-[N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline maleate:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 1.000 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 346 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to microorganisms	:	EC50 (Natural microorganism): > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

### 12.2 Persistence and degradability

No data available

## 12.3 Bioaccumulative potential

No data available

#### 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

## 12.6 Other adverse effects

## Product:

Endocrine disrupting poten- tial	:	The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation
		(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at
		levels of 0.1% or higher.

## **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product

: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.

## **Enalapril Formulation**



Version 3.4	Revision Date: 09.04.2021	SDS Number: 734752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016
Conta	aminated packaging	discussion with : Empty contain dling site for re	should be assigned by the user, preferably in h the waste disposal authorities. ers should be taken to an approved waste han- ecycling or disposal. e specified: Dispose of as unused product.
SECTION 14: Transport information			

## 14.1 UN number

Not regulated as a dangerous good

## 14.2 UN proper shipping name

Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

Not regulated as a dangerous good

## 14.4 Packing group

Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

#### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks

: Not applicable for product as supplied.

## **SECTION 15: Regulatory information**

## 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this	product are reported in	n the following inventories:
The components of this	produot die reported i	in the following inventories.

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## **SECTION 16: Other information**

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Stat	ements	
H302	:	Harmful if swallowed.
H319	:	Causes serious eye irritation.
H360D	:	May damage the unborn child.



## **Enalapril Formulation**

Vers 3.4	sion	Revision Date: 09.04.2021		S Number: 4752-00011	Date of last issue: 10.10.2020 Date of first issue: 07.06.2016			
	H372		:	Causes damage t exposure.	o organs through prolonged or repeated			
	Full text of other abbreviations							
	Acute Tox. Eye Irrit. Repr. STOT RE ZA OEL ZA OEL / TWA OEL-RL		<ul> <li>Acute toxicity</li> <li>Eye irritation</li> <li>Reproductive toxicity</li> <li>Specific target organ toxicity - repeated exposure</li> <li>South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits</li> <li>Long term occupational exposure limits - recommended limit</li> </ul>					
	ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada) ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Con- centration associated with x% response; ELx - Loading rate associated with x% response; EmS							

Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified: NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA -Toxic Substances Control Act (United States): UN - United Nations: UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

## Further information

Sources of key data used to	:
compile the Safety Data	
Sheet	

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

# Classification of the mixture:Classification procedure:Repr. 1AH360DCalculation methodSTOT RE 2H373Calculation method



## **Enalapril Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.4	09.04.2021	734752-00011	Date of first issue: 07.06.2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN